1-Formyl-LSD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1-Formyl-LSD, also known as 1-formyl-N,N-diethyllysergamide and sometimes referred to as 1F-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is the 1-formyl derivative of LSD.[1][2][3]
- None
| |
 | |
| Clinical data | |
|---|---|
| Other names | 1-Formyl-LSD; 1-Formyl-N,N-diethyllysergamide; N,N-Diethyl-1-formyl-6-methyl-9,10-didehydroergoline-8β-carboxamide; 1F-LSD |
| Routes of administration | Oral; Sublingual |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C21H25N3O2 |
| Molar mass | 351.450 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Another drug, 1‐(furan‐2‐carbonyl)‐LSD (SYN-L-005), has also been referred to as "1F-LSD".[3]
Use and effects
The drug is assumed to act as a prodrug of LSD.[1] It produces psychedelic effects in humans similarly to LSD.[2] Effective doses have been reported to be 100 to 150 μg orally or sublingually.[2] Very little is known about the pharmacology and properties of 1-formyl-LSD.[1]
Interactions
History
1-Formyl-LSD was first described in the scientific literature by 2021.[2] It first emerged as a novel designer drug online in January 2019.[1][2]
Society and culture
Legal status
Canada
1-Formyl-LSD is not an explicitly nor implicitly controlled substance in Canada as of 2025.[4]
United States
1-Formyl-LSD is not an explicitly controlled substance in the United States.[5] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.